[A24-96] Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V
Last updated 06.03.2025
Project no.:
A24-96
Commission:
Commission awarded on 15.09.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Treatment of pulmonary arterial hypertension in adult patients with WHO Functional Class II to III, to improve exercise capacity
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-96_en
| Project no. | Title | Status |
|---|---|---|
| A25-14 | Sotatercept (pulmonary arterial hypertension) – Addendum to Project A24-96 | Commission completed |
Federal Joint Committee (G-BA)
2025-03-06 A G-BA decision was published.